Active surveillance testing to reduce transmission of carbapenem-resistant, gram-negative bacteria in intensive care units: a pragmatic, randomized cross-over trial

Table 3 Clinical manifestations and outcomes between the intervention and control periods

	Intervention period (n = 590)	Control period (n = 724)	P value
Clinical diagnosis of infectious diseases
Hospital-acquired bloodstream infection	0	1 (0.1)	0.37
CRPA	0	0	–
CRAB	0	1 (0.1)	0.37
CRE	0	0	–
Catheter-related bloodstream infection	0	1 (0.1)	0.37
CRPA	0	0	–
CRAB	0	1 (0.1)	0.37
CRE	0	0	-
Urinary tract infection	0	1 (0.1)	0.37
CRPA	0	0	-
CRAB	0	0	-
CRE	0	1 (0.1)	0.37
Catheter-associated urinary tract infection	0	1 (0.1)	0.37
CRPA	0	0	–
CRAB	0	0	–
CRE	0	1 (0.1)	0.37
Pneumonia	0	4 (0.6)	0.07
CRPA	0	2 (0.3)	0.20
CRAB	0	2 (0.3)	0.20
CRE	0	1 (0.1)	0.37
Ventilator-associated pneumonia	0	3 (0.4)	0.12
CRPA	0	2 (0.3)	0.20
CRAB	0	1 (0.1)	0.37
CRE	0	1 (0.1)	0.37
Death			–
In-ICU mortality^a	70 (11.9)	76 (10.5)	0.43

CRPA carbapenem-resistant P. aeruginosa; CRAB carbapenem-resistant A. baumannii; CRE carbapenem-resistant Enterobacterales
The data are shown as no. (%) unless otherwise indicated
^aDeath during the follow-up periods (until 2 days after ICU discharge)

ISSN: 2047-2994